These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25476584)

  • 1. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
    de Menezes Martins R; Curran B; Maia Mde L; Ribeiro Md; Camacho LA; da Silva Freire M; Yamamura AM; Siqueira MM; Lemos MC; de Albuquerque EM; von Doellinger Vdos R; Homma A; Saganic L; Jarrahian C; Royals M; Zehrung D
    Contemp Clin Trials; 2015 Mar; 41():1-8. PubMed ID: 25476584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection.
    Sarno MJ; Blase E; Galindo N; Ramirez R; Schirmer CL; Trujillo-Juarez DF
    Pediatr Infect Dis J; 2000 Sep; 19(9):839-42. PubMed ID: 11001106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
    Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
    Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T; Eda M; Hirano M; Goto W
    Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
    Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
    Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
    Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model.
    Coughlin MM; Collins M; Saxon G; Jarrahian C; Zehrung D; Cappello C; Dhere R; Royals M; Papania M; Rota PA
    Vaccine; 2015 Aug; 33(36):4540-7. PubMed ID: 26192359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
    Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
    Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
    McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
    Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.